Form PTO-1449 (modified)	Atty. Docket No. MYOG:034USC1	Serial No. 10/801,985
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Carlin Long *et al.*	
	Filing Date: March 16, 2004	Group: ~~Unknown~~ 1614

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 2*

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	US 2002/0103192	8/1/02	Curtin *et al.*	514	227.8	3/14/01
	A2	US 2002/0061860	5/23/02	Li *et al.*	514	44	8/6/01
	A3	US 2002/0065282	5/30/02	Georges *et al.*	514	238.2	12/4/01

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	EP 1170008	1/9/02	Europe			
	B2	EP 1174438	1/23/02	Europe			
	B3	JP 2001/348340	12/18/01	Japan			Abstract
	B4	WO 00/23112	4/27/00	PCT			
	B5	WO 00/71703	11/30/00	PCT			
	B6	WO 01/14581	3/1/01	PCT			
	B7	WO 01/16106	3/8/01	PCT			
	B8	WO 01/18045	3/15/01	PCT			
	B9	WO 01/38322	5/31/01	PCT			
	B10	WO 01/42437	6/14/01	PCT			
	B11	WO 01/70675	9/27/01	PCT			
	B12	WO 02/051842	7/4/02	PCT			
	B13	WO 02/26696	4/4/02	PCT			
	B14	WO 02/26703	4/4/02	PCT			
	B15	WO 02/30879	4/18/02	PCT			
	B16	WO 02/46129	6/13/02	PCT			
	B17	WO 02/46144	6/13/02	PCT			

25433944.1

EXAMINER: [signature] | DATE CONSIDERED: 9/14/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. MYOG:034USC1	Serial No. 10/801,985
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Carlin Long *et al.*	
	Filing Date: March 16, 2004	Group: ~~Unknown~~ 1614

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 2*

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B18	WO 02/50285	6/27/02	PCT			
	B19	WO 01/17514	3/15/01	PCT			

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Bates *et al.*, "A phase I study of FR901228(Depsipeptide), a histone deacetylase inhibitor," *American Society of Clinical Oncology Meeting 1999 Abstract*, Abstract # 693, 1999, printed from www.medespace.com/cancero/doc/asco/1999/nouvdro/m_693.htm, May 7, 2001.
	C2	Butler *et al.*, "Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase," *Clin. Cancer Res.*, 7:962-970, 2001.
	C3	Butler *et al.*, "Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo," *Cancer Res.*, 60:5165-5170, 2000.
	C4	Coffey *et al.*, "The histone deacetylase inhibitor, CBHA, inhibits growth of human neuroblastoma xenografts in vivo, alone and synergistically with all-trans retinoic acid," *Cancer Res.*, 61:3591-3594, 2001.
	C5	Furumai *et al.*, "FK228 (Depsipeptide) as a natural prodrug that inhibits class I histone deacetylases," *Cancer Res.*, 62:4916-4921, 2002.
	C6	Gottlicher *et al.*, "Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells," *EMBO J.*, 20:6969-6978, 2001.
	C7	Han *et al.*, "Apicidin, a histone deacetylase inhibitor, inhibits proliferation of tumor cells via induction of $p21^{WAF1/Cip1}$ and gelsolin," *Cancer Research*, 60:6068-6074, 2000.
	C8	Haq, "Glycogen synthase kinase-3β is a negative regulator of cardiomyocyte hypertrophy," *J. Cell Biology*, 151:117-129, 2000.
	C9	Hinnebusch *et al.*, "The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation," *J. Nutr.*, 132:1012-1017, 2002.
	C10	Hoffmann *et al.*, "Fluorescence-labeled octapeptides as substrates for histone deacetylase," *Bioconjugate Chem.*, 12:51-55, 2001.

25433944.1

EXAMINER: _____ DATE CONSIDERED: 9/16/04

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP 609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. MYOG:034USC1	Serial No. 10/801,985
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Carlin Long *et al.*	
	Filing Date: March 16, 2004	Group: ~~Unknown~~ 1614

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 2*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C11	Itazaki *et al.*, "Isolation and structural elucidation of new cyclotetrapeptides, trapoxins A and B, having detransformation activities as antitumor agents," *J Antibiot (Tokyo)*, 43(12):1524-1532, 1990.
	C12	Jung *et al.*, "Amide analogues of trichostatin A as inhibitors of histone deacetylase and inducers of terminal cell differentiation," *J. Med. Chem.*, 42:4669-4679, 1999.
	C13	Jung *et al.*, "Analogues of trichostatin A and trapoxin B as histone deacetylase inhibitors," *Bioorganic & Medicinal Chemistry Letters*, 7:1655-1658, 1997.
	C14	Jung *et al.*, "Structure-activity data on inhibitors of histone deacetylase-in vivo enzyme inhibition of differentiation and inhibition of proliferation in leukemic cells," *Clin. Cancer Res., Suppl.* 6: Abstract #336, 2000.
	C15	Jung, "Inhibitors of histone deacetylase as new anticancer agents," *Curr. Med. Chem.*, 8:1505-1511, 2001.
	C16	Katoh *et al.*, "MEF2B is a component of a smooth muscle-specific complex that binds an A/T-rich element important for smooth muscle myosin heavy chain gene expression," *J. Biol. Chem.*, 273:1511-1518, 1998.
	C17	Kim *et al.*, "Oxamflatin is a novel antitumor compound that inhibits mammalian histone deacetylase," *Oncogene*, 18:2461-2470, 1999.
	C18	Kitazono *et al.*, "Low concentrations of the histone deacetylase inhibitor, depsipeptide (FR901228), increase expression of the Na^+/I^- symporter and iodine accumulation in poorly differentiated thyroid carcinoma cells," *J. Clinical Endoc. Metabol.*, 86(7):3430-3435, 2001.
	C19	Komastsu *et al.*, "Cyclic hydroxamic-acid-containing peptide 31, a potent synthetic histone deacetylase inhibitor with antitumor activity," *Cancer Res.*, 61:4459-4466, 2001.
	C20	Kramer *et al.*, "Histone deacetylase as a therapeutic target," *Trends in Endoc. Metabolism*, 12(7):294-300, 2001.
	C21	Lu *et al.*, "Signal-dependent activation of the MEF2 transcription factor by dissociation from histone deacetylases," *Proc. Natl Acad. Sci. USA*, 97:4070-4075, 2000.
	C22	Mai *et al.*, "Binding mode analysis of 3-(4-benzoyl-1-methyl-1H-2-pyrrolyl)-N-hydroxyy-2-propenamide: a new synthetic histone deacetylase inhibitor inducing histone hyperacetylation, growth inhibition, and terminal cell differentiation," *J. Med. Chem.*, 45:1778-1784, 2002.

25433944.1

EXAMINER: [signature] | DATE CONSIDERED: 9/16/2004

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. MYOG:034USC1	Serial No. 10/801,985
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Carlin Long *et al.*	
	Filing Date: March 16, 2004	Group: ~~Unknown~~ 1614

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 2*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C23	Marks *et al.*, "Histone deacetylase inhibitors: inducers of differentiation or apoptosis of transformed cells," *J. Natl. Cancer Inst.*, 92(15):1210-1216, 2000.
	C24	Marks *et al.*, "Inhibitors of histone deacetylase are potentially effective anticancer agents," *Clin. Cancer Res.*, 7:759-760, 2001.
	C25	Massa *et al.*, "3-(4-Aroyl-1H-pyrrol-2-yl)-N-hydroxy-2-propenamides, a new class of synthetic histone deacetylase inhibitors," *J. Med. Chem.*, 44:2069-2072, 2001.
	C26	Nicol *et al.*, "Activated MEK5 induces serial assembly of sarcomeres and eccentric cardiac hypertrophy," *The EMBO J.*, 20(11):2757-2767, 2001.
	C27	Patrone *et al.*, "Up regulation of the RET gene expression by histone deacetylase inhibitor sodium butyrate: hints to the gene physiologic regulation and applications for mutations screening," *50th Annual Meeting of the American Society of Human Genetics, Abstracts*, Program Number 1047, 2000.
	C28	Salminen *et al.*, "Neuronal apoptosis induced by histone deacetylase inhibitors," *Brain Res. Mol. Brain Res.*, 61:203-206, 1998.
	C29	Saunders *et al.*, "Histone deacetylase inhibitors as potential anti-skin cancer agents," *Cancer Res.*, 59-399-409, 1999.
	C30	Skaletz-Rorowski *et al.*, "The histone deacetylase inhibitors, trichostatin A and the new synthetic inhibitor M232, suprress the proliferation of corornary smooth muscle cells," *Eur. Heart J.*, Abstract Suppl., 21:272, Abstract #P1551, August/September 2000.
	C31	Su *et al.*, "A novel histone deacetylase inhibitor identified by high-throughput transcriptional screening of a compound library," *Cancer Res.*, 60:3137-3142, 2000.
	C32	Takahashi *et al.*, "Selective inhibition of IL-2 gene expression by trichostatin A, a potent inhibitor of mammalian histone deacetylase," *Antibiotics*, 49:453-457, 1996.
	C33	Taunton *et al.*, "A mammalian histone deacetylase related to the yeast transcriptional regulator Rpd3p," *Science*, 272:408-411, 1996.
	C34	Ueda *et al.*, "FR901228, a novel antitumor bicyclic depsipeptide produced by Chromobacterium violaceum No. 968. I. Taxonomy, fermentation, isolation, physico-chemical and biological properties, and antitumor activity," *J Antibiot (Tokyo)*, 47(3):301-310, 1994.

25433944.1

EXAMINER: [signature] | DATE CONSIDERED: 9/16/2004

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)	Atty. Docket No. MYOG:034USC1	Serial No. 10/801,985
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT (Use several sheets if necessary)	Applicant Carlin Long *et al.*	
	Filing Date: March 16, 2004	Group: ~~Unknown~~ 1614

U.S. Patent Documents	Foreign Patent Documents	Other Art
See Page 1	*See Page 1*	*See Page 2*

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C35	Vigushin *et al.*, "Histone deacetylase inhibitors in cancer treatment," *Anticancer Drugs*, 13:1-13, 2002.
	C36	Vigushin *et al.*, "Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo," *Cancer Res.*, 5(Suppl), Abstract #239, 1999.
	C37	Vigushin *et al.*, "Trichostatin A is a histone deacetylase inhibitor with potent antitumor activity against breast cancer in vivo," *Clinical Cancer Res.*, 7:971-976, 2001.
	C38	Yamano *et al.*, "Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase," *3rd Annual Meeting of the American Society of Gene Therapy*, Program Number 10, 2000.
	C39	Yamano *et al.*, "Amplification of transgene expression in vitro and in vivo using a novel inhibitor of histone deacetylase," *Mol. Ther., Amer. Society of Gene Ther.*, 1(5):S20, Abstract #10, 2000.
	C40	Yamano *et al.*, "Construction and function of a recombinant adeno-associated virus encoding human interleukin-10," *Mol. Ther., Amer. Society of Gene Ther.*, 1(5):S276, Abstract #764, 2000.

25433944.1

EXAMINER: [signature] | DATE CONSIDERED: 9/16/2004

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.